Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2022-09-27 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于完成注册资本工商变更登记的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the completion of a change in registered capital and related business registration updates. It details the company's share repurchase and cancellation of restricted stock, adjustments to total share capital and registered capital, and the completion of the industrial and commercial registration change. The document does not contain financial statements or detailed financial performance data. It is a formal announcement of a capital change and registration update rather than a full financial report or detailed management discussion. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is short (1744 characters), and it is not merely a report publication announcement but a substantive announcement of capital changes.
2022-09-27 Chinese
关于复方银花解毒颗粒获得新加坡注册批文的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about receiving a new drug registration approval from the Singapore Health Sciences Authority. It details the product information, registration number, clinical trials, and the impact on the company. The document is relatively short (1349 characters) and serves as a formal announcement of a regulatory approval rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed financial data. It is not an annual report, earnings release, or any other detailed financial or governance report. It is a regulatory announcement about product registration approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-09-27 Chinese
2022年员工持股计划第一次持有人会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the 2022 employee stock ownership plan first holders meeting of Yifan Pharmaceutical Co., Ltd. It details the meeting attendance, voting results, and decisions regarding the establishment and election of the management committee for the employee stock ownership plan, as well as authorization of the committee to handle related matters. The document is not a financial report, earnings release, or regulatory filing but rather an announcement of meeting resolutions related to employee stock ownership plan governance. It does not fit into categories like Annual Report, Interim Report, or Capital Update. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about corporate governance related to employee stock ownership plan management, and does not fit more specific categories such as Board/Management Information or Proxy Solicitation. The document length is 2342 characters, which is relatively short and consistent with an announcement rather than a full report.
2022-09-26 Chinese
2022年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2022 first extraordinary general meeting of shareholders of 亿帆医药股份有限公司. It includes information about the meeting date, attendance, voting results on various proposals, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official voting results and procedural details of the shareholders' meeting rather than presenting financial data, management discussion, or other report types. The document length is 2475 characters, which is relatively short and consistent with a voting results announcement. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-09-16 Chinese
安徽天禾律师事务所关于亿帆医药股份有限公司2022年第一次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, voting procedures, and resolutions of a company's 2022 first extraordinary general meeting (临时股东大会). It details the legal compliance of the meeting process and the validity of the resolutions passed. The document is not a report of financial results, audit, or management discussion, but a legal opinion on the shareholder meeting. It includes voting results and confirms the legality and validity of the meeting and resolutions. This type of document corresponds to a Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes and related shareholder meeting information. The document length is under 5,000 characters and contains detailed voting results and legal opinions, not just an announcement of a report publication or a regulatory filing. Therefore, the correct classification is DVA with high confidence.
2022-09-16 Chinese
安徽天禾律师事务所关于亿帆医药股份有限公司2022年员工持股计划（草案）之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding a company's 2022 employee stock ownership plan (ESOP) draft. It extensively discusses the legal compliance, procedures, and regulatory adherence of the employee stock ownership plan, referencing relevant Chinese securities laws and regulatory guidelines. It does not contain financial statements, earnings data, or audit results. It is not an announcement of a report but a legal advisory document. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal opinion related to a corporate action rather than a financial report or announcement of voting results.
2022-09-07 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.